Markin Rodney S 4

What Happened
Rodney S. Markin, a director of Cardiff Oncology, was granted 40,565 shares (reported as a derivative award) on June 11, 2026. The Form 4 lists an acquisition price of $0.00 for the award, so the filing shows $0 in purchase consideration. This was an equity grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11
• Transaction type/code: Award/Grant (A); reported as a derivative acquisition
• Price reported: $0.00 per share (total reported consideration $0)
• Shares involved: 40,565 shares granted
• Shares owned after transaction: Not specified in the provided filing details
• Filing date: 2026-06-15 — appears to be filed within the standard 2-business-day window for Form 4s
• No footnotes or 10b5-1 / tax-withholding details were included in the provided summary

Context
Director grants are commonly part of routine compensation (e.g., restricted stock or RSUs) and do not, by themselves, indicate the insider is buying or selling based on a view of near-term stock performance. Because this was an awarded derivative security (no cash paid per the filing), it should be viewed as a compensation/retention event rather than a market bet.